CRISPR-Cas9 Gene Editing May Select for Cells With Cancer-Related Mutations
By Sophia Ktori,
Genetic Engineering & Biotechnology News
| 11. 12. 2021
A comprehensive study headed by researchers at Sanford Burnham Prebys has shown that gene editing—specifically gene knockout (KO)—using CRISPR-Cas9 technology can favor cells with mutated forms of p53 or KRAS genes linked to cancer. The researchers say the findings highlight the need to monitor patients undergoing CRISPR-Cas9-based gene therapy for cancer-related mutations.
“Our study shows that in many different cell types, CRISPR gene-editing can confer a selective advantage to cells harboring mutations in genes associated with cancer, such as p53 and KRAS,” said co-senior author Ani Deshpande, PhD, an assistant professor in the NCI-Designated Cancer Center at Sanford Burnham Prebys. “We have shown that when CRISPR-Cas9 is used to edit the genome, cells with cancer-associated mutations are likely to be selected to survive—and this is more widespread than scientists previously understood.”
Deshpande and colleagues reported on their studies in Nature Communications, in a paper titled, “A systematic genome-wide mapping of oncogenic mutation selection during CRISPR-Cas9 genome editing.”
CRISPR-Cas9 works by creating double-stranded DNA breaks at specific points in a DNA sequence, allowing scientists to target and edit...
Related Articles
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Judith Levine, The Intercept | 04.04.2024
WHEN THE ALABAMA Supreme Court ruled that fertilized embryos were “extrauterine children,” it did more than imperil the future of in vitro fertilization in Alabama and, potentially, the U.S. The ruling, on the claimed “wrongful death” of frozen embryos...